

Joseph F Costello

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8707820/publications.pdf>

Version: 2024-02-01

70
papers

5,907
citations

147566

31
h-index

123241

61
g-index

72
all docs

72
docs citations

72
times ranked

11627
citing authors

#	ARTICLE	IF	CITATIONS
1	PI3K/AKT/mTOR signaling pathway activity in IDH-mutant diffuse glioma and clinical implications. <i>Neuro-Oncology</i> , 2022, 24, 1471-1481.	0.6	14
2	<i>TERT</i> promoter C228T mutation in neural progenitors confers growth advantage following telomere shortening <i>in vivo</i> . <i>Neuro-Oncology</i> , 2022, 24, 2063-2075.	0.6	9
3	Imaging biomarkers of TERT or GABPB1 silencing in TERT-positive glioblastoma. <i>Neuro-Oncology</i> , 2022, , .	0.6	3
4	Meningioma DNA methylation groups identify biological drivers and therapeutic vulnerabilities. <i>Nature Genetics</i> , 2022, 54, 649-659.	9.4	93
5	Deuterium Metabolic Imaging Reports on TERT Expression and Early Response to Therapy in Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 3526-3536.	3.2	15
6	Functional analysis of low-grade glioma genetic variants predicts key target genes and transcription factors. <i>Neuro-Oncology</i> , 2021, 23, 638-649.	0.6	9
7	Early Noninvasive Metabolic Biomarkers of Mutant IDH Inhibition in Glioma. <i>Metabolites</i> , 2021, 11, 109.	1.3	15
8	Cancer-specific loss of <i>TERT</i> activation sensitizes glioblastoma to DNA damage. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	28
9	miRNA-independent function of long noncoding pri-miRNA loci. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	18
10	Temozolomide-induced hypermutation is associated with distant recurrence and reduced survival after high-grade transformation of low-grade <i>IDH</i> -mutant gliomas. <i>Neuro-Oncology</i> , 2021, 23, 1872-1884.	0.6	48
11	Metabolic imaging detects elevated glucose flux through the pentose phosphate pathway associated with TERT expression in low-grade gliomas. <i>Neuro-Oncology</i> , 2021, 23, 1509-1522.	0.6	15
12	Spatial concordance of DNA methylation classification in diffuse glioma. <i>Neuro-Oncology</i> , 2021, 23, 2054-2065.	0.6	19
13	Non-invasive assessment of telomere maintenance mechanisms in brain tumors. <i>Nature Communications</i> , 2021, 12, 92.	5.8	21
14	Unique challenges for glioblastoma immunotherapy—discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology. Meeting Report from the 2019 SNO Immuno-Oncology Think Tank. <i>Neuro-Oncology</i> , 2021, 23, 356-375.	0.6	59
15	Epigenomic contributions to tumor cell heterogeneity and plasticity. <i>Nature Genetics</i> , 2021, 53, 1403-1404.	9.4	3
16	The DNA methylation landscape of advanced prostate cancer. <i>Nature Genetics</i> , 2020, 52, 778-789.	9.4	198
17	Epigenomic programming in early fetal brain development. <i>Epigenomics</i> , 2020, 12, 1053-1070.	1.0	9
18	Prostate Cancer Progression and the Epigenome. <i>New England Journal of Medicine</i> , 2020, 383, 2287-2290.	13.9	5

#	ARTICLE	IF	CITATIONS
19	Glutamate Is a Noninvasive Metabolic Biomarker of IDH1-Mutant Glioma Response to Temozolomide Treatment. <i>Cancer Research</i> , 2020, 80, 5098-5108.	0.4	18
20	Multiplatform genomic profiling and magnetic resonance imaging identify mechanisms underlying intratumor heterogeneity in meningioma. <i>Nature Communications</i> , 2020, 11, 4803.	5.8	56
21	Patient-derived cells from recurrent tumors that model the evolution of IDH-mutant glioma. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa088.	0.4	16
22	Gliomas arising in the setting of Li-Fraumeni syndrome stratify into two molecular subgroups with divergent clinicopathologic features. <i>Acta Neuropathologica</i> , 2020, 139, 953-957.	3.9	18
23	MGMT promoter methylation level in newly diagnosed low-grade glioma is a predictor of hypermutation at recurrence. <i>Neuro-Oncology</i> , 2020, 22, 1580-1590.	0.6	55
24	Multiplatform Molecular Profiling Reveals Epigenomic Intratumor Heterogeneity in Ependymoma. <i>Cell Reports</i> , 2020, 30, 1300-1309.e5.	2.9	11
25	PATH-12. TEMOZOLOMIDE-INDUCED HYPERMUTATION IS ASSOCIATED WITH HIGH-GRADE TRANSFORMATION, DISTANT RECURRENCE AND REDUCED SURVIVAL IN INITIALLY LOW GRADE IDH-MUTANT GLIOMAS. <i>Neuro-Oncology</i> , 2020, 22, ii166-ii166.	0.6	2
26	EPCO-36. GENOMIC INSTABILITY AND TRANSCRIPTOMIC SIGNATURES UNDERLYING EPIGENETIC MENINGIOMA SUBGROUPS REVEALS MECHANISMS OF IMMUNE INFILTRATION AND THERAPEUTIC VULNERABILITIES. <i>Neuro-Oncology</i> , 2020, 22, ii77-ii77.	0.6	0
27	BIOM-19. METABOLIC ALTERATION INDUCED BY SELECTIVE KNOCK DOWN OF GABPB1L IN U251 CELLS. <i>Neuro-Oncology</i> , 2020, 22, ii5-ii6.	0.6	0
28	TAMI-08. A TALE OF TWO TELOMERE MAINTENANCE MECHANISMS: TERT EXPRESSION AND THE ALT PATHWAY INDUCE UNIQUE MRS-DETECTABLE METABOLIC REPROGRAMMING IN LOW-GRADE GLIOMAS. <i>Neuro-Oncology</i> , 2020, 22, ii214-ii214.	0.6	0
29	BIOM-38. PI3K/AKT/mTOR SIGNALING PATHWAY ACTIVITY IN IDH-MUTANT DIFFUSE GLIOMA. <i>Neuro-Oncology</i> , 2020, 22, ii9-ii10.	0.6	0
30	EPCO-31. EPIGENOMIC INTRATUMORAL HETEROGENEITY OF GLIOBLASTOMA IN THREE-DIMENSIONAL SPACE. <i>Neuro-Oncology</i> , 2020, 22, ii76-ii76.	0.6	2
31	Recurrent KBTBD4 small in-frame insertions and absence of DROSHA deletion or DICER1 mutation differentiate pineal parenchymal tumor of intermediate differentiation (PPTID) from pineoblastoma. <i>Acta Neuropathologica</i> , 2019, 137, 851-854.	3.9	45
32	TMOD-27. A NEURAL CREST CELL SUBPOPULATION UNDERLIES INTRATUMOR HETEROGENEITY IN MENINGIOMA. <i>Neuro-Oncology</i> , 2019, 21, vi268-vi268.	0.6	1
33	CSIG-24. GABP LINKS AMPK SIGNALING TO TERT REGULATION IN A TERT PROMOTER MUTATION DEPENDENT MANNER. <i>Neuro-Oncology</i> , 2019, 21, vi49-vi49.	0.6	1
34	IMMU-11. SPATIOTEMPORAL IMMUNOGENOMIC ANALYSIS OF THE T-CELL REPERTOIRE IN IDH-MUTANT LOWER GRADE GLIOMAS. <i>Neuro-Oncology</i> , 2019, 21, vi121-vi121.	0.6	0
35	GENE-47. A 3D ATLAS TO EVALUATE THE SPATIAL PATTERNING OF GENETIC ALTERATIONS AND TUMOR CELL STATES IN GLIOMA. <i>Neuro-Oncology</i> , 2019, 21, vi107-vi108.	0.6	0
36	GENE-43. TARGETING GABPB1L INHIBITS IN VIVO GROWTH OF TERT PROMOTER MUTANT GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2019, 21, vi106-vi107.	0.6	0

#	ARTICLE	IF	CITATIONS
37	Genomic Profiling of BDE-47 Effects on Human Placental Cytotrophoblasts. <i>Toxicological Sciences</i> , 2019, 167, 211-226.	1.4	32
38	Temozolomide-associated hypermutation in gliomas. <i>Neuro-Oncology</i> , 2018, 20, 1300-1309.	0.6	130
39	Glioma through the looking GLASS: molecular evolution of diffuse gliomas and the Glioma Longitudinal Analysis Consortium. <i>Neuro-Oncology</i> , 2018, 20, 873-884.	0.6	119
40	Antigenic expression and spontaneous immune responses support the use of a selected peptide set from the IMA950 glioblastoma vaccine for immunotherapy of grade II and III glioma. <i>Oncolmunology</i> , 2018, 7, e1391972.	2.1	42
41	Genomic analysis of the origins and evolution of multicentric diffuse lower-grade gliomas. <i>Neuro-Oncology</i> , 2018, 20, 632-641.	0.6	33
42	The long non-coding RNA <i>HOTAIR</i> is transcriptionally activated by HOXA9 and is an independent prognostic marker in patients with malignant glioma. <i>Oncotarget</i> , 2018, 9, 15740-15756.	0.8	28
43	Disruption of the β 21L Isoform of GABP Reverses Glioblastoma Replicative Immortality in a TERT Promoter Mutation-Dependent Manner. <i>Cancer Cell</i> , 2018, 34, 513-528.e8.	7.7	103
44	Chemotherapy for adult low-grade gliomas: clinical outcomes by molecular subtype in a phase II study of adjuvant temozolomide. <i>Neuro-Oncology</i> , 2017, 19, now176.	0.6	70
45	DNA methylation: an epigenetic mark of cellular memory. <i>Experimental and Molecular Medicine</i> , 2017, 49, e322-e322.	3.2	286
46	Treatment-Induced Mutagenesis and Selective Pressures Sculpt Cancer Evolution. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2017, 7, a026617.	2.9	59
47	Comprehensive Analysis of Hypermutation in Human Cancer. <i>Cell</i> , 2017, 171, 1042-1056.e10.	13.5	596
48	Clonal expansion and epigenetic reprogramming following deletion or amplification of mutant <i>IDH1</i> . <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 10743-10748.	3.3	109
49	Probing the phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway in gliomas: A phase 2 study of everolimus for recurrent adult low-grade gliomas. <i>Cancer</i> , 2017, 123, 4631-4639.	2.0	43
50	Somatic and Germline <i>TP53</i> Alterations in Second Malignant Neoplasms from Pediatric Cancer Survivors. <i>Clinical Cancer Research</i> , 2017, 23, 1852-1861.	3.2	29
51	Genome-wide DNA methylation is predictive of outcome in juvenile myelomonocytic leukemia. <i>Nature Communications</i> , 2017, 8, 2127.	5.8	75
52	Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas. <i>Journal of Clinical Investigation</i> , 2017, 127, 1425-1437.	3.9	334
53	CBIO-02. MUTANT IDH EXPRESSION DRIVES TERT PROMOTER REACTIVATION AS PART OF THE CELLULAR TRANSFORMATION PROCESS. <i>Neuro-Oncology</i> , 2016, 18, vi35-vi35.	0.6	0
54	Intratumoral Heterogeneity of the Epigenome. <i>Cancer Cell</i> , 2016, 29, 440-451.	7.7	172

#	ARTICLE	IF	CITATIONS
55	Mutant IDH1 Expression Drives <i>TERT</i> Promoter Reactivation as Part of the Cellular Transformation Process. <i>Cancer Research</i> , 2016, 76, 6680-6689.	0.4	55
56	Understanding <i>TERT</i> Promoter Mutations: A Common Path to Immortality. <i>Molecular Cancer Research</i> , 2016, 14, 315-323.	1.5	222
57	Oncogene brought into the loop. <i>Nature</i> , 2016, 529, 34-35.	13.7	6
58	Mutant IDH1 expression is associated with down-regulation of monocarboxylate transporters. <i>Oncotarget</i> , 2016, 7, 34942-34955.	0.8	32
59	MPTH-29CONNECTING MUTANT GENOTYPES TO ABERRANT TRANSCRIPTIONAL SIGNATURES ACROSS SERIAL SECTIONS OF A HUMAN TUMOR. <i>Neuro-Oncology</i> , 2015, 17, v144.4-v145.	0.6	0
60	HIGD1A Regulates Oxygen Consumption, ROS Production, and AMPK Activity during Glucose Deprivation to Modulate Cell Survival and Tumor Growth. <i>Cell Reports</i> , 2015, 10, 891-899.	2.9	79
61	Epigenetic and transcriptional determinants of the human breast. <i>Nature Communications</i> , 2015, 6, 6351.	5.8	56
62	Evolution of DNA repair defects during malignant progression of low-grade gliomas after temozolomide treatment. <i>Acta Neuropathologica</i> , 2015, 129, 597-607.	3.9	143
63	The transcription factor GABP selectively binds and activates the mutant <i>TERT</i> promoter in cancer. <i>Science</i> , 2015, 348, 1036-1039.	6.0	451
64	The genomic landscape of juvenile myelomonocytic leukemia. <i>Nature Genetics</i> , 2015, 47, 1326-1333.	9.4	233
65	DNA Methylation and Somatic Mutations Converge on the Cell Cycle and Define Similar Evolutionary Histories in Brain Tumors. <i>Cancer Cell</i> , 2015, 28, 307-317.	7.7	221
66	Regulatory network decoded from epigenomes of surface ectoderm-derived cell types. <i>Nature Communications</i> , 2014, 5, 5442.	5.8	25
67	Transcription Restores DNA Repair to Heterochromatin, Determining Regional Mutation Rates in Cancer Genomes. <i>Cell Reports</i> , 2014, 9, 1228-1234.	2.9	104
68	Mutational Analysis Reveals the Origin and Therapy-Driven Evolution of Recurrent Glioma. <i>Science</i> , 2014, 343, 189-193.	6.0	1,147
69	Restriction Landmark Genomic Scanning: Analysis of CpG Islands in Genomes by 2D Gel Electrophoresis. <i>Methods in Molecular Biology</i> , 2009, 507, 131-148.	0.4	17
70	DNA methylation in brain development and gliomagenesis. <i>Frontiers in Bioscience - Landmark</i> , 2003, 8, s175-184.	3.0	44